secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tectonic Therapeutic, Inc. (TECX)
CIK:        0001681087
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001193125-24-188881
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tectonic Therapeutic receives FDA IND clearance for lead program TX45 in PH-HFpEF
--------------------------------------------------------------------------------

- FDA cleared IND for TX45 (Fc-relaxin fusion) for Group 2 PH due to HFpEF, a condition with no approved therapy affecting >600K US patients.
- Phase 1a healthy volunteer topline results due September 2024; Phase 1b patient hemodynamic topline results expected mid-2025.
- Phase 2 trial to start Q3 2024: 24-week SC dosing, up to 180 subjects; primary endpoint PVR change. Topline results anticipated in 2026.
- TX45 engineered for optimized pharmacology targeting vasodilation, diastolic dysfunction, and remodeling to improve exercise capacity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681087/000119312524188881/0001193125-24-188881-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681087/000119312524188881/d783068d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-188881

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer